These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 31371221)

  • 1. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    Jain P; Nogueras González GM; Kanagal-Shamanna R; Rozovski U; Sarwari N; Tam C; Wierda WG; Thompson PA; Jain N; Luthra R; Quesada A; Sanchez-Petitto G; Ferrajoli A; Burger J; Kantarjian H; Cortes J; O'Brien S; Keating MJ; Estrov Z
    Br J Haematol; 2018 Jan; 180(1):33-40. PubMed ID: 29164608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
    Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
    Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
    Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FCR achieves long-term durable remissions in patients with
    Chai-Adisaksopha C; Brown JR
    Blood; 2017 Nov; 130(21):2278-2282. PubMed ID: 29025740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
    Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
    Pepper AGS; Zucchetto A; Norris K; Tissino E; Polesel J; Soe Z; Allsup D; Hockaday A; Ow PL; Hillmen P; Rawstron A; Catovsky D; Bulian P; Bomben R; Baird DM; Fegan CD; Gattei V; Pepper C
    Leukemia; 2022 Jan; 36(1):271-274. PubMed ID: 34148055
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
    Thompson PA; O'Brien SM; Xiao L; Wang X; Burger JA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG
    Cancer; 2016 Feb; 122(4):565-73. PubMed ID: 26588193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
    Nguyen-Khac F; Baron M; Guièze R; Feugier P; Fayault A; Raynaud S; Troussard X; Droin N; Damm F; Smagghe L; Susin S; Leblond V; Dartigeas C; Van den Neste E; Leprêtre S; Bernard OA; Roos-Weil D;
    Br J Haematol; 2024 Aug; 205(2):495-502. PubMed ID: 38654616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
    Lucas DM; Ruppert AS; Lozanski G; Dewald GW; Lozanski A; Claus R; Plass C; Flinn IW; Neuberg DS; Paietta EM; Bennett JM; Jelinek DF; Gribben JG; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS; Byrd JC; Grever MR
    Leuk Lymphoma; 2015; 56(11):3031-7. PubMed ID: 25721902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere length predicts for outcome to FCR chemotherapy in CLL.
    Norris K; Hillmen P; Rawstron A; Hills R; Baird DM; Fegan CD; Pepper C
    Leukemia; 2019 Aug; 33(8):1953-1963. PubMed ID: 30700843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
    Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
    Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
    Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I
    Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
    Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
    Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.